(Q38074590)

28 August 2017

1 reference

title

ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC. (English)

1 reference

28 August 2017

4

1 reference

28 August 2017

9

Cesare Gridelli

1 reference

28 August 2017

8

Fortunato Ciardiello

1 reference

28 August 2017

Francesca Casaluce

1

1 reference

28 August 2017

Assunta Sgambato

2

1 reference

28 August 2017

Paolo Maione

3

1 reference

28 August 2017

Carmine Ferrara

5

1 reference

28 August 2017

Alba Napolitano

6

1 reference

28 August 2017

Giovanni Palazzolo

7

1 reference

28 August 2017

17 January 2013

1 reference

28 August 2017

1 reference

28 August 2017

8

1 reference

28 August 2017

1

1 reference

28 August 2017

55-67

1 reference

https://scigraph.springernature.com/pub.10.1007/s11523-012-0250-9

28 August 2017

0 references

cites work

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0250-9

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0250-9

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0250-9

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0250-9

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0250-9

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0250-9

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0250-9

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0250-9

A mouse model for EML4-ALK-positive lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0250-9

Anaplastic lymphoma kinase (ALK)-induced malignancies: novel mechanisms of cell transformation and potential therapeutic approaches.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0250-9

Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0250-9

Echinoderm microtubule-associated protein like protein 4, a member of the echinoderm microtubule-associated protein family, stabilizes microtubules

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0250-9

Human EML4, a novel member of the EMAP family, is essential for microtubule formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0250-9

Pathobiology of ALK+ anaplastic large-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0250-9

The anaplastic lymphoma kinase in the pathogenesis of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0250-9

The biology and treatment of EML4-ALK non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0250-9

Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0250-9

EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0250-9

Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0250-9

KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0250-9

EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0250-9

EML4-ALK fusion lung cancer: a rare acquired event

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0250-9

EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0250-9

EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0250-9

The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0250-9

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0250-9

Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0250-9

EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0250-9

EML4-ALK: honing in on a new target in non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0250-9

Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0250-9

Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0250-9

Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0250-9

Bronchoscopic microsampling is a useful complementary diagnostic tool for detecting lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0250-9

Combination of morphological feature analysis and immunohistochemistry is useful for screening of EML4-ALK-positive lung adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0250-9

EML4-ALK fusion gene assessment using metastatic lymph node samples obtained by endobronchial ultrasound-guided transbronchial needle aspiration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0250-9

Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0250-9

Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0250-9

Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0250-9

The potential for crizotinib in non-small cell lung cancer: a perspective review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0250-9

Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0250-9

An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0250-9

Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0250-9

Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0250-9

CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0250-9

CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0250-9

Antitumor activity of pyridoisoquinoline derivatives F91873 and F91874, novel multikinase inhibitors with activity against the anaplastic lymphoma kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0250-9

1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profile.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0250-9

GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0250-9

Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0250-9

Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0250-9

Design and synthesis of a novel tyrosine kinase inhibitor template

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0250-9

Synthesis and structure-activity relationships of 1,2,3,4-tetrahydropyrido[2,3-b]pyrazines as potent and selective inhibitors of the anaplastic lymphoma kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0250-9

Virtual screening and further development of novel ALK inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0250-9

Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0250-9

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0250-9

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0250-9

Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0250-9

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0250-9

Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0250-9

Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0250-9

ROS1 rearrangements define a unique molecular class of lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0250-9

Treating ALK-positive lung cancer--early successes and future challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0250-9

Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0250-9

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0250-9

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0250-9

Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0250-9

Successful long-term treatment with pemetrexed of NSCLC associated with EML4-ALK and low thymidylate synthase expression

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23325296

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

TRK-fused gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFG-ALK translocations

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23325296

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23325296

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S11523-012-0250-9

1 reference

Dimensions Publication ID

28 August 2017

0 references

1 reference